BioSkryb is a developer of genomic amplification technologies that delivers higher coverage and fidelity for gene sequencing.
BioSkryb's technology provides an unprecedented coverage and fidelity for various gene sequencing applications.
BioSkryb was founded in 2018 by Jay West and Charles Gawad. The company is headquartered in Durham, North Carolina. Its proprietary genome amplification technology was developed at St. Jude Children's Research Hospital in Memphis, TN.
BioSkryb's proprietary genomic amplification technology allows scientists working with scarce genetic material to achieve high quality gene sequencing data. The technology provides uniform coverage of almost the entire genome, allowing for unparalleled accuracy in DNA variant calling.
Bioskryb’s SkrybAmp technology, powered by Primary Template Directed Amplification (PTA), enables even coverage of the entire genome during DNA amplification and allows for unprecedented accuracy and uniformity in DNA sequence coverage and base calling – the identification of the individual DNA bases.
BioSkryb has raised $11.5M in a Seed round of funding on Jan 09, 2020. The round was led by venture capital firm Anzu Partners and included the law firm Wilson Sonsini Goodrich & Rosati.